Literature DB >> 12430872

Current study of APL treatment in China.

Dao-Pei Lu1, Qin Wang.   

Abstract

Natural As4S4 and As2S3 are major components in realgar and orpiment, which also contain small amount of As2O3 and other toxic materials. Liu YF showed with us that NB4 cell line and its mice model were more sensitive to As4S4 than to As2O3 and As2S3. That was in agreement with the clinical data available from China. Wang FR and we proved in mice and in clinical pharmaceutical study that ground Seman platycladi as an excipient can appreciably increase the blood level of arsenic when taken P.O. together with As4S4. Our clinical study with 130 patients with t(15;17) APL showed both As4S4 and As2S3 alone were very effective in CR induction, including cytogenetic remission and PML-RAR reversion, yet the relapse rate was higher in the group treated by As4S4 alone than in the group treated together with other autileukemic agents, either together or in sequence. In the later group, LFS for 1 and 6 years was 96.7% and 87.4%, and the over-all survival for 1 and 6 years was 98.9% and 93.9%. High dose chemotherapy was proven to be not only unsafe but also unnecessary. In newly diagnosed APL patients with neutropenia, CR could be safely achieved by As4S4 P.O. and/with ATRA. Chemotherapy was then followed. In patients with leukocytosis, chemotherapeutic agents such as hydroxyurea or harringtonine was added at the beginning and then followed by anthracycline and asparaginase. The reasons of APL relapse after patients receiving As4S4 P.O. were: 1: emergence of a resistant cell clone showing additional chromosomal abnormalities other than t(15;17); 2: decrease of blood As level. The resistant APL case could respond favorably to combination of As4S4 P.O. together with ATRA. The blood level of As could be raised by modification of the preparation under investigation. Allogeneic stem cell transplantation (allo-SCT) is the last option in relapsed patients, became autologous stem cell transplantation (ASCT) has a significantly better outcome. In a few hospitals ASCT was performed early in the CR1. In rare cares, patients were referred with intra-cranial hemorrhage. CT or EMR scan was done urgently at this instance. Cranial surgery carried out without a minute of delay resulted in the rescue and long survival of patient, while delay of surgery had resulted in irreversible damage of Pons/Medulla oblongata and ended in death. As2O3 IV had been used with success in mentally unclear patients not suffering from intra-cranial hemorrhage. Although no parallel clinical trial has been done to compare the efficacy of As2O3 and As4S4, yet the fact was it was easier for doctors and patients to carry out and receive maintenance treatment with oral As4S4 rather than with As2O3. According to the data and principles above, most of the t(15;17) APL patients can be cured.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12430872     DOI: 10.1007/bf03165273

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  10 in total

1.  Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery.

Authors:  Qi-Hong Zhao; Ying Zhang; Yun Liu; Hui-Li Wang; Yuan-Yuan Shen; Wen-Jun Yang; Long-Ping Wen
Journal:  Med Oncol       Date:  2009-03-12       Impact factor: 3.064

2.  Inhibition of hepatitis C virus replication by arsenic trioxide.

Authors:  Der-Ren Hwang; Yuan-Chin Tsai; Jin-Ching Lee; Kuo-Kuei Huang; Ren-Kuo Lin; Chia-Hua Ho; Jeng-Min Chiou; Ying-Ting Lin; John T A Hsu; Chau-Ting Yeh
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

3.  Absorption Characteristics of Combination Medication of Realgar and Indigo Naturalis: In Vitro Transport across MDCK-MDR1 Cells and In Vivo Pharmacokinetics in Mice after Oral Administration.

Authors:  Miao Zhang; Lin Guo; Long-Fei Lin; Chang-Hai Qu; Xing-Bin Yin; Shi-Lin Luo; Xin Zhang; Hai-Ying Zhang; Xiao Liang; Jun Guan; Jian Ni
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-06       Impact factor: 2.629

Review 4.  Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes.

Authors:  Elden P Swindell; Patrick L Hankins; Haimei Chen; Denana U Miodragović; Thomas V O'Halloran
Journal:  Inorg Chem       Date:  2013-10-22       Impact factor: 5.165

5.  Anticancer efficacies of arsenic disulfide through apoptosis induction, cell cycle arrest, and pro-survival signal inhibition in human breast cancer cells.

Authors:  Yuxue Zhao; Bo Yuan; Kenji Onda; Kentaro Sugiyama; Sachiko Tanaka; Norio Takagi; Toshihiko Hirano
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

Review 6.  Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview).

Authors:  Peter Baláž; Ján Sedlák
Journal:  Toxins (Basel)       Date:  2010-06-21       Impact factor: 4.546

7.  Effect of size and processing method on the cytotoxicity of realgar nanoparticles in cancer cell lines.

Authors:  Weizhong Zhao; Xun Lu; Yuan Yuan; Changsheng Liu; Baican Yang; Hua Hong; Guoying Wang; Fanyan Zeng
Journal:  Int J Nanomedicine       Date:  2011-08-02

8.  Arsenic sulfide as a potential anti‑cancer drug.

Authors:  Wenping Ding; Lian Zhang; Sungkyoung Kim; Wei Tian; Yingying Tong; Jianwen Liu; Yong Ma; Siyu Chen
Journal:  Mol Med Rep       Date:  2014-11-03       Impact factor: 2.952

9.  Realgar (As4S4), a traditional Chinese medicine, induces acute promyelocytic leukemia cell death via the Bcl-2/Bax/Cyt-C/AIF signaling pathway in vitro.

Authors:  Zonghong Li; Ruiming Zhang; Xuewei Yin; Nana Li; Siyuan Cui; Teng Wang; Xing Tan; Mingyue Shen; Yun Guo; Jinxin Wang; Dadong Guo; Ruirong Xu
Journal:  Aging (Albany NY)       Date:  2022-09-12       Impact factor: 5.955

10.  Enhanced antitumor activity of realgar mediated by milling it to nanosize.

Authors:  Ye Tian; Xiaobo Wang; Ronggang Xi; Weisan Pan; Shuang Jiang; Zhao Li; Yu Zhao; Guanghui Gao; Dan Liu
Journal:  Int J Nanomedicine       Date:  2014-01-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.